Starpharma Holdings Limited (SPL.AX)
AUD 0.1
(1.02%)
AUD 0.1
(1.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 7.65 Million AUD | 526.34% |
| 2023 | 1.22 Million AUD | -35.86% |
| 2022 | 1.9 Million AUD | 253.29% |
| 2021 | 539.5 Thousand AUD | -87.25% |
| 2020 | 4.23 Million AUD | 71.41% |
| 2019 | 2.46 Million AUD | -50.19% |
| 2018 | 4.95 Million AUD | 35.92% |
| 2017 | 3.64 Million AUD | -20.27% |
| 2016 | 4.57 Million AUD | 169.53% |
| 2015 | 1.69 Million AUD | 35.43% |
| 2014 | 1.25 Million AUD | 6165.0% |
| 2013 | 20 Thousand AUD | -97.84% |
| 2012 | 925 Thousand AUD | -19.14% |
| 2011 | 1.14 Million AUD | -18.52% |
| 2010 | 1.4 Million AUD | -30.46% |
| 2009 | 2.01 Million AUD | 42.99% |
| 2008 | 1.41 Million AUD | 63.45% |
| 2007 | 863.85 Thousand AUD | 172670.8% |
| 2006 | 500.00 AUD | -99.98% |
| 2005 | 2.04 Million AUD | 47.37% |
| 2004 | 1.39 Million AUD | -6.35% |
| 2003 | 1.48 Million AUD | 285.99% |
| 2002 | 384.7 Thousand AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 6.42 Million AUD | 0.0% |
| 2024 Q4 | -3.49 Million AUD | 0.0% |
| 2024 FY | 7.09 Million AUD | 480.74% |
| 2023 Q2 | -69 Thousand AUD | 0.0% |
| 2023 FY | 1.22 Million AUD | -35.86% |
| 2023 Q4 | 985 Thousand AUD | 0.0% |
| 2022 FY | 1.9 Million AUD | 253.29% |
| 2022 Q4 | 1 Million AUD | 0.0% |
| 2022 Q2 | 385 Thousand AUD | 0.0% |
| 2021 Q2 | -250 Thousand AUD | 0.0% |
| 2021 Q4 | 807 Thousand AUD | 0.0% |
| 2021 FY | 539.5 Thousand AUD | -87.25% |
| 2020 Q4 | -15 Thousand AUD | 0.0% |
| 2020 Q2 | 4.24 Million AUD | 0.0% |
| 2020 FY | 4.23 Million AUD | 71.41% |
| 2019 FY | 2.46 Million AUD | -50.19% |
| 2019 Q2 | 661 Thousand AUD | 0.0% |
| 2019 Q4 | 1.17 Million AUD | 0.0% |
| 2018 Q4 | 3.71 Million AUD | 0.0% |
| 2018 FY | 4.95 Million AUD | 35.92% |
| 2018 Q2 | 1.24 Million AUD | 0.0% |
| 2017 Q2 | 549 Thousand AUD | 0.0% |
| 2017 FY | 3.64 Million AUD | -20.27% |
| 2016 FY | 4.57 Million AUD | 169.53% |
| 2016 Q2 | 3.74 Million AUD | 0.0% |
| 2015 Q4 | 964 Thousand AUD | 0.0% |
| 2015 Q2 | 733 Thousand AUD | 0.0% |
| 2015 FY | 1.69 Million AUD | 35.43% |
| 2014 FY | 1.25 Million AUD | 6165.0% |
| 2014 Q4 | 532 Thousand AUD | 0.0% |
| 2014 Q2 | 721 Thousand AUD | 0.0% |
| 2013 Q2 | 1.29 Million AUD | 11672.73% |
| 2013 Q1 | 11 Thousand AUD | 0.0% |
| 2013 Q3 | 5000.00 AUD | -99.61% |
| 2013 Q4 | 1.13 Million AUD | 22680.0% |
| 2013 FY | 20 Thousand AUD | -97.84% |
| 2012 Q1 | 286 Thousand AUD | 0.0% |
| 2012 FY | 925 Thousand AUD | -19.14% |
| 2012 Q4 | 11 Thousand AUD | 0.0% |
| 2012 Q3 | 11 Thousand AUD | 0.0% |
| 2012 Q2 | 11 Thousand AUD | -96.15% |
| 2011 FY | 1.14 Million AUD | -18.52% |
| 2011 Q3 | 286 Thousand AUD | 0.0% |
| 2011 Q1 | 351 Thousand AUD | 0.0% |
| 2011 Q4 | 286 Thousand AUD | 0.0% |
| 2011 Q2 | 286 Thousand AUD | -18.52% |
| 2010 Q3 | 351 Thousand AUD | 0.0% |
| 2010 FY | 1.4 Million AUD | -30.46% |
| 2010 Q2 | 351 Thousand AUD | -30.46% |
| 2010 Q1 | 504.75 Thousand AUD | 0.0% |
| 2010 Q4 | 351 Thousand AUD | 0.0% |
| 2009 Q2 | 504.75 Thousand AUD | 42.99% |
| 2009 Q3 | 504.75 Thousand AUD | 0.0% |
| 2009 Q4 | 504.75 Thousand AUD | 0.0% |
| 2009 Q1 | 353 Thousand AUD | 0.0% |
| 2009 FY | 2.01 Million AUD | 42.99% |
| 2008 Q2 | 353 Thousand AUD | 63.45% |
| 2008 Q3 | 353 Thousand AUD | 0.0% |
| 2008 FY | 1.41 Million AUD | 63.45% |
| 2008 Q4 | 353 Thousand AUD | 0.0% |
| 2008 Q1 | 215.96 Thousand AUD | 0.0% |
| 2007 FY | 863.85 Thousand AUD | 172670.8% |
| 2007 Q4 | 215.96 Thousand AUD | 0.0% |
| 2007 Q1 | 125.00 AUD | 0.0% |
| 2007 Q3 | 215.96 Thousand AUD | 0.0% |
| 2007 Q2 | 215.96 Thousand AUD | 172670.4% |
| 2006 Q1 | 3480.50 AUD | 0.0% |
| 2006 Q4 | 125.00 AUD | 0.0% |
| 2006 Q3 | 125.00 AUD | 0.0% |
| 2006 FY | 500.00 AUD | -99.98% |
| 2006 Q2 | 125.00 AUD | -96.41% |
| 2005 FY | 2.04 Million AUD | 47.37% |
| 2005 Q3 | 3480.50 AUD | 0.0% |
| 2005 Q4 | 3480.50 AUD | 0.0% |
| 2005 Q2 | 3480.50 AUD | -11.49% |
| 2005 Q1 | 3932.50 AUD | 0.0% |
| 2004 Q4 | 3932.50 AUD | 0.0% |
| 2004 Q1 | 227.83 Thousand AUD | 0.0% |
| 2004 Q2 | 3932.50 AUD | -98.27% |
| 2004 Q3 | 3932.50 AUD | 0.0% |
| 2004 FY | 1.39 Million AUD | -6.35% |
| 2003 Q2 | 227.83 Thousand AUD | 136.89% |
| 2003 Q4 | 227.83 Thousand AUD | 0.0% |
| 2003 Q3 | 227.83 Thousand AUD | 0.0% |
| 2003 Q1 | 96.17 Thousand AUD | 0.0% |
| 2003 FY | 1.48 Million AUD | 285.99% |
| 2002 Q4 | 96.17 Thousand AUD | 0.0% |
| 2002 Q3 | 96.17 Thousand AUD | 0.0% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 Q2 | 96.17 Thousand AUD | 0.0% |
| 2002 FY | 384.7 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 Q2 | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2001 Q3 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1999 Q1 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1998 Q4 | - AUD | 0.0% |
| 1998 Q2 | - AUD | 0.0% |
| 1998 Q3 | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -407.787% |
| Acrux Limited | -1.28 Million AUD | 696.34% |
| Race Oncology Limited | 1.38 Million AUD | -450.897% |
| Biome Australia Limited | 7.66 Million AUD | 0.165% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 216.873% |
| BTC Health Limited | 16.36 Thousand AUD | -46703.178% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -2.727% |
| CSL Limited | 15.28 Billion AUD | 99.95% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 33.456% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 90.196% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 84.97% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 1.44 Million AUD | -430.298% |
| Memphasys Limited | 1606.00 AUD | -476674.595% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 96.268% |
| Noxopharm Limited | -534.81 Thousand AUD | 1531.721% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -106.257% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 135.935% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -4987.336% |
| Biotron Limited | -40.49 Thousand AUD | 19007.107% |
| Alterity Therapeutics Limited | 3.8 Million AUD | -101.236% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 1122.419% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 2640.065% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -74355.465% |
| Patrys Limited | 1.39 Million AUD | -449.218% |
| Orthocell Limited | 3.68 Million AUD | -107.596% |
| Imugene Limited | -5.83 Million AUD | 231.116% |
| PYC Therapeutics Limited | 22.05 Million AUD | 65.289% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 781.72% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -230.664% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 29573.806% |
| Nanollose Limited | -348.95 Thousand AUD | 2294.285% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -531.632% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 8483.24% |
| Amplia Therapeutics Limited | 4.01 Million AUD | -90.912% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -511.789% |
| Nyrada Inc. | -5164.07 AUD | 148374.52% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 97.518% |
| Dimerix Limited | 583.47 Thousand AUD | -1212.303% |
| PharmAust Limited | -1641.00 AUD | 466705.728% |
| AnteoTech Limited | 460.39 Thousand AUD | -1563.13% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -13377.786% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 2187.696% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 17583.731% |
| Actinogen Medical Limited | 9.93 Million AUD | 22.902% |
| Immuron Limited | 3.33 Million AUD | -129.472% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -194.734% |